Our results provide an interesting proof-of-concept for the therapeutic targeting of H3K36me3 remodeling to inhibit the progression of liver fibrosis promoted by abnormal menin/SETD2 inactivation. This evidence concerns the gene SETD2 and Hepatic fibrosis.